Our Executive Team
Dr. Peter Skarsgard, MD
Dr. Skarsgard is a Cardiovascular Surgeon and Clinical Professor of Surgery at the University of British Columbia, and Head of the Division of Cardiovascular Surgery at Vancouver General Hospital. His area of expertise is mitral valve repair and complex valvular surgery. Based upon a simple clinical observation, Dr. Skarsgard developed and patented concepts for devices aimed toward percutaneous treatment of mitral regurgitation, utilizing proven surgical principles. These ideas form the basis for Calla-TC3 and CrossCut.
Vincent Ledoux, MSc
Chief Operating officer
Mr. Ledoux is a Business and Strategy Specialist with a background in Corporations and Investment Banking worldwide. Since 2009, he has been deeply involved in startups - launching, advising and mentoring engineering and technology ventures directly, and through the University of British Columbia Lean LaunchPad. Vincent holds a Bachelor of Science in Economics and a Master of Science in Business Management from EMLyon Business School in France. While bringing valuable corporate and business inputs, Vincent will coordinate the R&D.
Ian McDougall, BASc (Mech Eng)
Chief Technology Officer
Mr. McDougall has been active in medical device development in Vancouver for more than 20 years, mainly focused on endovascular products, both cardiac and peripheral. He is co-founder of five medical technology startups, and has substantial engineering, regulatory, and clinical trial experience that has led to the successful launch of device ventures from concept to market approval. A "Top 40 Under 40" recipient from Business In Vancouver Magazine, Ian will provide engineering, device design, and regulatory advisory to Vesalius Cardiovascular.
Dr. Jacqueline Saw, MD
Chief Medical Officer
Dr. Saw is a Clinical Professor of Medicine at the University of British Columbia, and a Structural Interventional Cardiologist at the Vancouver General Hospital. She is a recognized expert and key opinion leader in percutaneous device delivery, left atrial appendage occlusion, and spontaneous coronary artery dissection. Her contributions in CT imaging, pre-procedural planning, device selection, and device delivery have enabled acceleration of evolving structural interventions. She has considerable clinical trial experience, and has been a driving force for understanding women's health in cardiovascular disease. Dr. Saw will lead the pre-procedure planning and device delivery effort, and bring important clinical trial design input to Vesalius Cardiovascular.
Our Advisory Team
Dr. Richard Cook, MD
Surgical and Transcatheter Advisory
Dr. Cook is a Cardiovascular Surgeon and Clinical Associate Professor of Surgery at the University of British Columbia. He is Medical Director of Minimally Invasive Cardiac Surgery at Vancouver General Hospital, and an Examiner in Cardiac Surgery for the Royal College of Physicians and Surgeons of Canada. His areas of expertise are in minimally invasive mitral valve repair, robot-assisted coronary bypass surgery, and transcatheter heart valve therapy. Dr. Cook bridges surgical and percutaneous treatment of structural heart disease, and brings important clinical input to Vesalius Cardiovascular.
Dr. Christopher Durkin, MD
Dr. Durkin is a Clinical Assistant Professor of Anaesthesiology at the University of British Columbia, and a member of the Section of Cardiovascular Anaesthesiology at Vancouver General Hospital. In addition to expertise in cardiovascular physiology and pharmacology, he holds National Board of Echocardiography Certification in Advanced Perioperative Transesophageal Echocardiography, and is an expert in 3D echo for intracardiac structural disease and procedures. Dr. Durkin brings critical inputs in 3D echo imaging, both procedurally and in planning, to Vesalius Cardiovascular.
Vesalius in the news...
Vesalius successful at Cascadia Venture Forum Summit in Seattle
November 15, 2017 - Cambie Grove, Seattle.
Competing this time with the top finishers in each Regional Forum (BC, OR, and WA), Vesalius again finishes in first place at the Cascadia Venture Forum Summit in Seattle, from a field of 7 startup companies in the Seed category. Proof of Concept and Product Market Fit for the Vesalius mitral valve repair device convinced voters within the audience and panel.
We would like the thank Cascadia for this amazing opportunity.
As a part of this success, Vesalius is invited to engage with Keiretsu Forum, an Angel Investor community, with Deal Screening in December, and a Seed Deal pitch in Portland, Tacoma, Bellevue, Seattle and Vancouver, all in February 2018.
Vesalius pitches to Lumira Capital and other VCs at Invest in BC
October 18, 2017 - Terminal City Club, Vancouver.
Dr. Skarsgard, President of Vesalius Cardiovascular and inventor of the Calla-TC3 device, describes to investors how the Vesalius product line can benefit patients and fulfill the unmet need for patients with MR. Dr. Skarsgard explains how Calla-TC3 can relieve the “pains” of current surgical treatment, and provide “gains” for patients, providers, hospitals, and health institutions. See the slide deck for this event, coming soon.
Vesalius successful at Cascadia Venture Forum Vancouver
October 12, 2017 - VentureLabs, Vancouver.
Vesalius Cardiovascular finishes in first place at the Vancouver Cascadia Venture Forum, from a field of 6 startup ventures in the Seed category, as voted by the audience of angels, VCs, entrepreneurs, and business mentors. Vesalius will now proceed to the Cascadia Summit Competition to be held in Seattle on November 15, 2017.
Vesalius Cardiovascular Inc., 2016